| INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications, especially for inflammatory conditions such as osteoarthritis and arthropathies. However, these medications are known to cause upper gastrointestinal (GI) toxicities. Indeed, gastroduodenal ulcers have been found in 20%-30% of chronic NSAID users. 1, 2 Video capsule endoscopy (VCE) and balloon-assisted endoscopy have demonstrated that NSAIDs cause small bowel injuries more frequently than was previously recognised, 3, 4 but the clinical impact of numerous minimal small bowel injuries remains to be determined.
Anti-acid secretory drugs, especially proton pump inhibitors (PPIs), are considered the mainstay for prophylaxis against NSAIDinduced upper GI damage. However, in a recent study, we found some evidence that addition of rabeprazole to celecoxib increased in the amount of small bowel injury compared to subjects who took
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celecoxib alone (44.4% vs 16.7%, P=.04). 5 This observation suggested that the alteration of the luminal environment by concurrent PPI use could explain these phenomenona, 6 although further evidence is needed to confirm the exacerbation of NSAID-induced small bowel injury as the class effect of PPIs.
PPIs are metabolised in the liver by various enzymes, including cytochrome P450 2C19 (CYP2C19). 7, 8 Various CYP2C19 polymorphisms, particularly the homozygous extensive metabolizer (homEM), the heterozygous extensive metabolizer (hetEM), and the poor metabolizer (PM), 9, 10 correlate closely with PPI metabolism.
CYP2C19 genotype-dependent differences in pharmacokinetics and pharmacodynamics of PPIs have been shown to be associated with the rate of Helicobacter pylori eradication and the results of PPIbased treatments for gastroesophageal reflux disease (GERD). 11, 12 It thus seems possible that the risk of NSAID-induced small bowel injury may also correlate with CYP2C19 genotype. In the present study, we investigated the possible association of genetic polymorphisms in CYP2C19 with the incidence of NSAID-induced small bowel injury. This investigation was undertaken as a sub-analysis of our prospective, randomised, placebo-controlled study. 5 2 | ME TH ODS
| Subjects
We recruited healthy Japanese volunteers who participated in the PPI-NSAID Kyushu University study (PINK study; UMIN clinical trial registry number: UMIN000008883). 5 The PINK study was a randomised, double-blind, placebo-controlled trial investigating the effect of rabeprazole on celecoxib-induced small bowel injury. A total of 57 subjects were randomly assigned to either celecoxib (200 mg, twice daily) plus rabeprazole (20 mg, once daily) for 2 weeks (n=27), or celecoxib (200 mg, twice daily) plus placebo for 2 weeks (n=30). The primary endpoint of the PINK study was the incidence of small bowel mucosal injuries determined by VCE.
Among the subjects recruited for the PINK study, we were unable to contact two participants for the present study. Blood samples were collected from the remaining 55 participants after obtaining informed consent. Of these subjects, 26 were administered celecoxib plus rabeprazole (rabeprazole group), and 29 were treated with celecoxib plus placebo (placebo group). The present study was approved by the ethical committee of Kyushu University Hospital.
| Capsule endoscopy
The assessment of small bowel mucosal injuries by VCE is described in detail in our previous report. 5 Briefly, small bowel mucosal breaks were defined as positive VCE findings. These were further subdivided into ulcers or erosions. 
| Statistics
Numerical data were compared among groups using the Mann-Whitney U test, and categorical data were compared using Fisher's exact probability test. Logistic regression analysis was used for multivariate analysis. Hardy-Weinberg equilibrium (HWE) for the distribution of the CYP2C19 genotype was verified using the chi-squared test. We also examined the interaction between CYP2C19 genotypes (PM vs EM) and rabeprazole use for the risk of celecoxib-induced small bowel injury by applying an interaction term to the logistic regression analysis. Statistical analyses were performed using JMP software version 11.0 (SAS Institute, Tokyo, Japan). P<.05 were considered statistically significant.
| RESULTS

| CYP2C19 genotyping
In all subjects, genotyping of the seven CYP2C19 SNPs was successful. No genetic polymorphism was detected for CYP2C19*4, *5, *6, *7, or *8 in the study population ( Table 1 ). The genotype distribution of the remaining two SNPs (CYP2C19*2 and *3) was in accordance with HWE (P>.05). The minor allele frequency of each SNP was equivalent to that of the Japanese population, as shown in
HapMap-JPT.
| Baseline subject characteristics
Seven subjects in the rabeprazole group were regarded as PM, and the remaining 19 subjects as EM. A similar proportion of PM subjects (seven of 29, 24.1%) was found in the placebo group. Table 2 shows the baseline characteristics of PM and EM subjects in each group. Three subjects were taking concurrent medications. One PM subject in the rabeprazole group was taking amezinium metilsulfate (20 mg/d) for orthostatic hypotension, an EM subject in the placebo group was taking losartan potassium (50 mg/d) for hypertension, and a second EM subject in the placebo group was taking camostat mesilate (300 mg/d) for chronic pancreatitis.
| Incidence of small bowel injuries
The incidence of small bowel mucosal injuries in the rabeprazole and placebo groups was 46.2% and 17.2% respectively. In the rabeprazole group, the incidence of small bowel mucosal injuries in PM subjects was significantly higher than that in EM subjects (85.7% vs 31.6%, P=.026, Figure 1 ). A significant difference was also noted in the stratified analysis according to the lesion site ( Figure 2 ). However, no significant difference was found between PM and EM subjects in the placebo group (0% vs 22.7%, P=.30, Figure 1 ).
In the rabeprazole group, univariate analysis revealed a significant association between PM and small bowel injury (P=.011, odds ratio (OR): 13.0, 95% confidence interval (CI): 1.27-133.3). This association remained significant after adjusting for age, sex, and body weight in a multivariate logistic regression analysis (P=.005). We also found a significant interaction between CYP2C19 enzyme activity and rabeprazole use in a multivariate regression analysis (P=.007).
The incidence rates of small bowel mucosal injuries were comparable between PM and EM subjects in the placebo group, so no further analysis was performed.
| Number of small bowel injuries in the rabeprazole group
The number of mucosal injuries of PM subjects was significantly P=.01; Figure 3 ). Among the mucosal injuries, the number of 
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| DISCUSSION
In this retrospective analysis of a prospective, randomised, controlled study, we investigated the contribution of CYP2C19 genotypes to the risk of celecoxib-induced small bowel injury in subjects taking rabeprazole concurrently. We found that subjects with PM CYP2C19 genotypes had a significantly higher risk of celecoxib-induced small bowel injury than those with EM genotypes. We also found a significant interaction between CYP2C19 genotype and concomitant use of rabeprazole for the risk of celecoxib-induced small bowel injury.
These results indicate that the CYP2C19 genotype is a modifier of risk for celecoxib-induced small bowel injury with use of rabeprazole.
CYP2C19 encodes a liver enzyme, S-mephenytoin 4'-hydroxylase, which metabolises several clinically important drugs, including antiplatelet agents (clopidogrel), antiseizure drugs (mephenytoin), anxiolytics (diazepam) and PPIs. 14 Enzymatic activity has been shown to be associated with a proportion of CYP2C19 alterations. In particular, differences in enzymatic activity in the Japanese population can be explained by the combination of two point mutations (CYP2C19*2 in exon 5 and CYP2C19*3 in exon 4). 10 The clinical impact of such differences has been rigorously examined for the use of clopidogrel. [15] [16] [17] For the Japanese population, the CYP2C19 genotype is known to have a considerable impact on PPI use because the prevalence of PM tends to be higher in this population (18.8%-22.5%) 10,18 compared with Caucasians (2.8%-5.4%). 19, 20 PPIs are gastric acid inhibitors used for the treatment of various conditions including gastroduodenal ulcers, GERD, H. pylori infection, 21 and prophylaxis against NSAID-induced upper GI damage.
Because PPIs are mainly metabolised through the enzymatic activity of CYP2C19 in the liver, differences in this activity were shown to affect the eradication rate for H. pylori infection during triple therapy including lansoprazole, amoxicillin and clarithromycin (97.8% in PM vs 72.7% in homEM, P<.001).
11 It was also reported that the therapeutic efficacy of lansoprazole in GERD depends on the CYP2C19 genotype, 12 although this is not the case for the acid inhibitory effect of rabeprazole. Nevertheless, Shirai et al. found that intragastric pH values were significantly higher in PM subjects than in homEM subjects receiving rabeprazole treatment. 22 This indicates that the acid inhibitory effect of PPIs is impacted by the enzymatic activity of CYP2C19 in the liver.
In the present study, we demonstrated an increase in the risk of celecoxib-induced small bowel injury among subjects with the PM Recent reports have also indicated that the suppression of gastric acid secretion leads to dysbiosis of the small bowel. 25, 26 Our results are compatible with this because differences in acid suppression by rabeprazole caused by CYP2C19 genotypes appear to contribute to differences in dysbiosis of the small bowel. However, rabeprazole per se has not been shown to induce small bowel mucosal damage or inflammation. 6 In addition to the increased risk of celecoxib-induced small bowel injury, CYP2C19 genotype-instigated differences in acid suppression by rabeprazole might influence its clinical impact. In the present study, however, the number of small bowel ulcers thought to be clinically relevant did not differ between PM and EM subjects in the rabeprazole group, while the number of erosions was significantly greater in PM than EM individuals. The prevalence of small bowel ulcers was also similar in PM and EM subjects (data not shown). However, we were unable to determine the clinical impact of CYP2C19 genotypes on these values because of our small sample size. Further studies with more patients are therefore necessary to validate these findings.
There are several limitations to the present study. First, its small sample size might contribute to an apparent higher incidence of small bowel injuries of PM subjects in the rabeprazole group. Second, we did not measure plasma rabeprazole levels or intragastric pH. Third, we did not examine changes in bacterial flora in the small bowel, so did not directly show evidence of the effect of the CYP2C19 genotype on gastric acid suppression or celecoxib-induced small bowel injuries. Nevertheless, we believe that our results are adequate in the context of our previous clinical trials and those of other investigators. 12, 22, 27, 28 In conclusion, the present study demonstrated a higher inci- 
